Ab­b­Vie, Gen­mab land FDA OK for CD3xCD20 bis­pe­cif­ic, catch­ing up with Roche

Ab­b­Vie and Gen­mab have land­ed an ac­cel­er­at­ed FDA ap­proval for their CD3xCD20 bis­pe­cif­ic, adding an op­tion for pa­tients with re­lapsed/re­frac­to­ry large B cell lym­phoma. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER